key: cord-0331708-0mjuze28
authors: Okoro, Emmanuel Ugochukwu
title: Tumor necrosis factor induces cholesterol accumulation in human arterial endothelial cells through LDL receptor surface redistribution
date: 2020-11-12
journal: bioRxiv
DOI: 10.1101/2020.06.29.177873
sha: 9b3898605b99e2906f24425a8447c446b698c4e4
doc_id: 331708
cord_uid: 0mjuze28

Tumor necrosis factor alpha (TNFα) and low density lipoprotein (LDL) are important modulators of the atherosclerotic process. Here, the effect of TNFα on confluent primary human aortic endothelial cell (pHAEC) LDL-derived lipids and trafficking were investigated. TNFα promoted up to 2 folds increase in cellular cholesterol and could induce a massive increase in the non-hydrolysable tracer, Dil, by over 200 folds. The lipid increase was associated with increased 125I-LDL surface binding. Further, Dil-LDL cellular association was blocked by excess unlabeled LDL, but not oxidized LDL (oxLDL). Moreover, TNFα-induced Dil and cholesterol increase were enhanced by the endosomal pH-raising agent, chloroquine. Internalization of Dil-LDL was reduced by the scavenger receptor B1 (SR-B1) antagonist, BLT-1, and the LDLR family antagonist, proprotein convertase subtilisin/kexin type 9 (PCSK9), but not receptor associated protein (R AP). Additionally, surface accessible LDLR was higher in TNFα-treated cells by about 30 folds, without a significant change in total LDLR. Correspondingly, specific LDLR antibody blocked Dil-LDL internalization to undetectable levels, and Dil-apoE3-VLDL by 94%, but had no effect on Dil-HDL3 internalization. TNFα did not increase Dil-HDL3 cellular association. Further, ACAT inhibitor reduced cholesteryl esters, but not the total cholesterol increase induced by TNFα. On pHAECs grown on transwell inserts, TNFα did not enhance apical (AP) to basolateral (BL) LDL cholesterol or Dil release. It is concluded that TNFα induces LDLR surface localization and that LDLR does not promote AP to BL LDL transport across pHAECs.

TNFα was originally discovered as a tumorselective hemorrhagic factor (1, 2) . However, it is now recognized to have multiple cell-type dependent effects (3, 4) . Released as a 17 kD soluble protein from a transmembrane precursor by tumor necrosis factor converting enzyme (TACE) (5) (6) (7) , this cytokine mainly promotes changes that facilitate leukocyte (inflammatory) functions. (4, 8) . Acting through the rapid-acting transcription factor, nuclear factor kappa B (NF-kB), it can induce expression of proinflammatory mediators such as interleukin 1 and 2 (9, 10) . Likewise, it is capable of inducing apoptosis (11) (12) (13) , possibly through c-jun Nterminal kinase (JNK) activation (14) (15) (16) . Thus TNFɑ may clear way for passage of leukocytes through target epithelial cell apoptosis. On the other hand, it can induce proliferation of lymphocytes and fibroblasts (12, (17) (18) (19) . This ability to induce proliferation have been reported to be due to upregulation of growth factor receptors (20, 21) or growth factor release, such as vascular endothelial growth factor (VEGF) (21) (22) (23) .

Some report that TNFɑ is atherogenic (24-26). The pro-atherogenic arm of TNFɑ is in part due to its ability to enhance monocyte entry into the intima through induction of adhesion molecules on arterial endothelial cells. In atherosclerotic lesions, macrophages (27) and smooth muscle cells (27, 28) have been reported to express TNFɑ, where it acts on overlying endothelial cells to stimulate expression of leukocyte adhesion molecules such as E-selectin, vascular cell adhesion molecule-1 (VCAM-1), and intercellular adhesion molecule-1 (ICAM-1) (29, 30) . More, it induces expression of monocyte chemoattractant protein I (MCP-1) (31) , which stimulates gradient migration of lymphocytes and monocytes (32, 33) .

Still, TNFɑ can have a neutral or ambiguous effect on atherosclerosis development (34, 35) . For example, targeted elimination of tumor necrosis factor receptor (TNFR) have produced mixed results. TNFR1 has been reported to be anti-atherogenic (34, 36) , pro-atherogenic (24, 37, 38) , or neutral (39) . Likewise, TNFR2 has been reported to be pro-atherogenic (40) or neutral (34) . These conflicting results suggest that the mechanisms by which TNFɑ affects atherosclerosis development need further clarification. Of note, TNFɑ deletion is associated with elevated HDL cholesterol, but reduced LDL cholesterol, indicating that it regulates serum lipoprotein levels (25) .

Background inflammation is an independent risk factor for atherosclerotic cardiovascular disease (41) . Serum concentration of TNFɑ increases with severity of atherosclerotic lesion (42, 43) and age (44) . Thus, it has been reported to be about 200 folds higher in the atherosclerotic lesion than in the circulating blood (45) .

Although TNFɑ levels in the arterial wall are elevated in the late stages of atherosclerosis, this elevation need not occur late in the disease. Elevated native LDL, which is pro-atherogenic, (46, 47) , stimulates TNFɑ production in smooth muscle cells (48) . Further, viremia, bacteria, and other forms of microbial infections affecting the artery may lead to focal elevation of TNFɑ, which can initiate atherosclerosis development (49) . Certain endothelial dysfunctions, such as impaired NO release, are well-characterized in late atherosclerotic lesions (50) . However, other endothelial functions that may affect initiation and progression of atherosclerosis are not well known.

Unlike macrophages (51, 52) and smooth muscle cells (51, 53) , normal confluent endothelial cells are resistant to cholesterol accumulation (54) . However, fibro-fatty atherosclerotic lesions contain endothelial foam cells with intact monolayer (55) (56) (57) . In this report, I present evidence of non-inflammatory function of TNFɑ. It will be shown that TNFɑ increases pHAEC cholesterol and lipid accumulation through increased surface accessible low density lipoprotein receptor (LDLR).

TNFɑ enhances cholesterol accumulation and LDL binding to pHAECs. Atherosclerotic lesion is characterized by release of inflammatory cytokines, among which is TNFɑ. To evaluate the effect of TNFɑ on pHAECs cholesterol content, confluent pHAECs were treated with or without TNFɑ and the cellular cholesterol content was measured. As is shown in Figure 1A , TNFɑ significantly increased unesterified cholesterol, and to a greater degree, esterified cholesterol ( Figure 1B) . Figure 1A -B also show that the ability of TNFɑ to induce cholesterol accumulation plateaus at around 100 µg/ml LDL protein. To evaluate whether TNFɑ affects the ability of LDL to bind to the cells, 125 I-LDL binding was performed. Figure 1C shows that TNFɑ enhanced 125 I-LDL surface releasable 125 I-LDL at 4 °C, after the cells were pre-treated at 37 °C. The amount released increased in the presence of 20 folds unlabeled LDL. This indicates that the 125 I-LDL bound to some native LDL receptor. Further, cellassociated 125 I-LDL was also higher on TNFɑtreated pHAECs (Figure 1D) , indicating higher 125 I-LDL internalization.

Having demonstrated that TNFa promoted LDL binding to pHAECs (Figure 1 ), the requirement for oxidative modification of LDL was investigated. Particularly, TNFɑ has been reported to promote release of the reactive oxygen species, superoxide and hydrogen peroxide (58, 59) . Hence, experiments were performed to determine whether oxidative modification of LDL is a prerequisite to TNFɑinduced LDL binding. To visualize TNFɑinduced LDL binding and subsequent internalization, Dil-LDL was used.

As can be seen in Figure 2A , Dil accumulation within the pHAECs can be seen as intracellular clusters located primarily to either pole of the cell. This internalized Dil-LDL was significantly increased through TNFɑ pre-treatment ( Figure  2A-B) . It can also be seen in Figure 2A -B that excess unlabeled native LDL blocked binding and internalization of Dil-LDL to undetectable levels. This demonstrates that native LDL components, and therefore receptors, are required for Dil-LDL binding and internalization. Excess unlabeled oxLDL, on the other hand, had weaker effect on Dil-LDL association in control cells. It had no effect on TNFɑ-treated cells ( Figure 2B) . The weak suppression of Dil-LDL association under control conditions is not too surprising. It can be seen in Figure 2C that oxLDL retains some apoB moiety, which can explain the residual effect on Dil-LDL association. Figure 3A , 3 Figure 3B ). Next, cells were treated with increasing Dil-LDL concentration without ( Figure 3C ) or with TNFɑ ( Figure 3D ). As is shown in Figure 3C , 400 µg/ml Dil-LDL increased intracellular Dil level by about 50 folds compared to that at 1 µg/ml under control condition. Compared to Ctrl at 400 µg/ml Dil-LDL, TNFɑ increased the intracellular Dil by over 200 folds ( Figure 3D ).

TNFɑ-induced LDL lipid accumulation. The lowering of pH facilitates disintegration and degradation of internalized LDL through the lysosomal compartment. This degradation is suppressed by the pH-raising compound, chloroquine (60) . To evaluate whether a similar phenomenon occurs in pHAECs, the cells were treated in the presence or absence of chloroquine. The presence of chloroquine caused the Dil to accumulate circumferentially within the cells, presumably in defective lysosomal structures ( Figure 4A ). As can be seen in Figure 4A -B, chloroquine greatly enhanced Dil accumulation without TNFɑ. The presence of TNFɑ further increased the amount of chloroquine-induced cellular Dil. Chloroquine also increased 3 H-cholesterol level from [ 3 H]CE-LDL. However, it was not as pronounced as in the case of Dil ( Figure 4C ).

hepatocytes. Having found evidence that TNFɑ promotes cholesterol accumulation in pHAECs through enhanced endocytosis of native LDL, I next investigated what members of the LDLR family are responsible, in addition to the potential role of SR-B1. Specifically, LDLderived lipid accumulation have been shown to be increased by SR-B1 (61) (62) (63) . To investigate these possibilities, experiments were performed with their respective inhibitors. The data in Figure 5A -B show that blockage of SR-B1 selective uptake with BLT-1 reduced TNFɑinduced Dil-LDL internalization. Likewise, the pan-LDLR family blocker PCSK9 (64-66), but not RAP (67), suppressed the Dil accumulation.

SR-B1 and the LDLR family members are abundantly expressed in hepatocytes. Thus, to evaluate whether RAP activity is measurable in hepatocytes, the cells were treated with all the inhibitors ( Figure 5C ). The results show that the failure of RAP to inhibit Dil-LDL internalization is specific to pHAECs. Since RAP has been reported to be ineffective against LDLR (68) , the data point to LDLR as the most likely candidate.

Having pinpointed LDLR as a likely receptor through which TNFɑ induces cholesterol and Dil accumulation in pHAECs, I next evaluated the effect of TNFɑ on the LDLR protein product (Figure 6A-B) . The data show that TNFɑ did not significantly increase total LDLR. However, it greatly promoted association of surface LDLR to its antibody in the culture medium as demonstrated by enhanced upward shift of the LDLR protein ( Figure 6A ).

Up to now, the data suggest that SR-B1 and/or LDLR contributes to the mechanism by which TNFɑ induces Dil-LDL binding and internalization. To evaluate the roles of these receptors, experiments were performed to test SR-B1 surface expression with Dil-HDL3 (61, 63) and LDLR surface expression with Dil-LDL and Dil-apoE3-VLDL. Since lipid-bound apoE binds all the LDLR family members (69) , information about the type of family member involved can further be evaluated in the presence of specific LDLR antibody. Accordingly, the data in Figure 7A -B show that Dil-HDL3 internalization in pHAECs was not enhanced by TNFɑ. Further, LDLR antibody did not block Dil-HDL3 cellular association. In contrast, LDLR antibody blocked TNFɑ-induced Dil-LDL cell association to undetectable levels ( Figure 7C-D) and blocked TNFɑ-induced Dil-apoE3-VLDL association by approximately 94% (Figure 7E -F). The overall data thus demonstrate that LDLR is the dominant receptor for uptake of non-HDL lipoproteins in pHAECs, with or without TNFɑ.

TNFɑ induces surface redistribution of LDLR. The data presented in Figure 6 indicated that more surface LDLR are induced by TNFɑ. Having found that LDLR mediates TNFɑinduced LDL internalization without a significant change in the total protein ( Figure 6 ), I investigated the extent of surface LDLR differences through immune-fluorescent microscopy. As can be seen in Figure 8A , TNFɑ did not enhance association of control antibody with the cells, but significantly induced association with specific LDLR antibody by 30 minutes at 37 °C. This indicates that TNFɑ did not promote non-selective endocytic processes. The surface distribution of LDLR (arrows) and the internalization of the surface LDLR (arrow heads) in cells treated with TNFɑ can be seen in Figure 8B .

The total amount of surface LDLR bound by the antibody at 37 °C can be seen to increase with time. At 0, 5, 30, and 120 minutes, there was about 30, 50, 7, and 2 folds, respectively, more surface LDLR in TNFɑ-treated cells compared to control cells at the corresponding time ( Figure 8C-D) . This demonstrates that LDLR antibody rapidly binds surface LDLR in the case of TNFɑ-treated cells, plateauing by about 2 hours. This plateauing is consistent with the finding that the total LDLR is not significantly different between control and TNFɑ-treated pHAECs ( Figure 6 ).

It has been reported that TNFɑ induces cholesteryl ester accumulation in monocytes through enhanced ACAT activity in the presence of oxLDL (70). To evaluate the extent to which enhanced ACAT activity is responsible in raising pHAEC cholesterol in the presence of LDL, the cells were with or without ACAT inhibitor, Sandoz 58-035. As is reported in Figure 9A -B, inhibition of ACAT activity slightly raised the unesterified cholesterol, and significantly suppressed cholesteryl ester accumulation. Despite this inhibition, the TNFɑinduced total cholesterol accumulation, now mainly in the unesterified form, was not prevented (Figure 9A ,C). ACAT inhibition also reduced the total cholesterol in the cells, with or without TNFɑ stimulation ( Figure 9C ). This is a known effect of ACAT inhibition. The higher elevated unesterified cholesterol is more likely to be effluxed from the cells than the esterified one (71).

To address the effect of increased LDLR-mediated uptake of LDL on apical to basolateral LDL protein transport, the pHAECs were grown to confluence on transwell inserts, as shown in Figure 10A . 125 I-LDL detected in the BL medium was either non-intact ( Figure 10B ) or intact ( Figure 10C ). In Figure  10B , it is shown that unlabeled LDL competitor reduced the amount of non-intact 125 I-LDL in a TNFɑ-independent manner. In contrast, the unlabeled competitor had no effect on the intact 125 I-LDL measured in the BL medium ( Figure  10C ). The overall data thus indicate that the LDLR cargo is not efficiently trafficked in a polarized manner in pHAECs.

To determine whether LDLR facilitates AP to BL LDL lipid transport, the pHAECs on transwell inserts were incubated with LDL colabeled with Dil and 3 H-cholesteryl esters ( Figure 11A-B) . As can be seen in the figures, TNFɑ dose-dependently increased the accumulation of Dil-LDL on the pHAECs grown on transwell inserts, in the same manner as those grown on plastic dishes. Similar to pHAECs on plastic dishes, LDLR antibody significantly blocked uptake of Dil-LDL by pHAECs grown on transwell inserts. The corresponding uptake of 3 H-cholesteryl esters is shown in Figure 11C . The 3 H-cholesteryl ester accumulation induced by TNFɑ is blocked in the presence of antibody against LDLR. Surprisingly, LDLR blockage had no effect on the amount of measurable 3 H-choleseryl ester detectable in the BL medium ( Figure 11D ). This is consistent with the BL Dil-LDL, whose value was independent of TNFɑ treatment ( Figure  11E ).

Native LDL modification due to oxidation (72, 73) , aggregation (74) , or complex formation with proteoglycans (75-77) is known to promote cholesterol accumulation in macrophages. Although confluent arterial endothelial cells are resistant to cholesterol accumulation induced by lipoproteins, my results demonstrated that this can be altered in the presence of TNFɑ. Thus, LDL modification is not an absolute requirement for LDL-induced cholesterol or lipid accumulation. The data suggest that pHAECs, like macrophages, may be susceptible to changes related to excess cholesterol loading, including apoptosis, which is known to occur in the most advanced form of atherosclerotic lesions (78) .

Interestingly, bovine brain microvascular endothethial cells have been reported to promote apical to basolateral transport of LDL through LDLR (79) . It thus appears that LDLR trafficking in brain microvascular endothelial cells is different from human aortic endothelial cells. Additionally, it has been reported that AP to BL LDL transport occurs in vivo across arterial endothelial cells (80) . My findings suggest that this transport is probably not through LDLR. SR-BI, on the other hand, have been reported to bind LDL (61, 81, 82) . Since SR-B1 have been shown to cause AP to BL transport of HDL in bovine aortic endothelial cells (83) , it is possible that it can do the same for LDL in human aortic endothelial cells. However, the results indicate that LDLR is the dominant receptor utilized by pHAECs for LDL uptake. The binding of LDLR to RAP is controversial. On one hand, it has been reported to bind LDLR (84) , while others report the opposite (68) . My data suggest that if it binds LDLR, it does not interfere with the ability of LDLR to subsequently internalize LDL.

TNFɑ is a pleiotropic autocrine and paracrine mediator important in multiple signaling cascades that range from activating immune cells to fight viruses, bacteria, and cancer cells, to promoting entry of monocytes and lymphocytes into atherosclerotic lesions (85) (86) (87) . The latter process is recognized to be proatherogenic. TNFɑ has also been reported to play an important role in the current COVID-19 pandemic (88) . Thus, nonspecific disruption of TNFɑ activity in the animal interferes with many important biological functions (89). My finding that TNFɑ upregulates surface LDLR function in pHAECs implies that it is possible to regulate this process selectively, while leaving the beneficial functions of TNFɑ intact. Excess cholesteryl ester accumulation in arterial endothelial cells is likely to lead to endothelial dysfunction due, in part, to space disruption.

Native lipoproteins that are potentially atherogenic exist in the form of LDL and β-VLDL. Unlike normal VLDL which contains triglycerides and apoB as their major constituents, β-VLDL is enriched in apoE and cholesterol (90) . β-VLDL levels increase as the plasma cholesterol values increase in animals fed high cholesterol diet (91) . My finding that apoE-enriched Dil-VLDL produced a marked increase in Dil accumulation, further enhanced by TNFɑ, suggest that it can initiate endothelial dysfunction in an LDLR-dependent manner. In addition to carrying cholesterol and cholesteryl esters as its primary cargo, LDL may transport other lipid soluble agents. Thus lipid-soluble drugs carried by non-HDL lipoproteins are predicted to negatively impact endothelial cells in the setting of infections, chronic inflammatory stress, and atherosclerosis.

The significantly greater Dil accumulation over cholesterol indicates that pHAECs have an efficient mechanism of overcoming enhanced LDL uptake. Neutral cholesteryl ester hydrolase activity and endosomal recycling are known to be intact in the presence of chloroquine (63, 92) . My data suggest that LDL-derived [ 3 H]CE may be hydrolysed outside the lysosome in pHAECs. This type of hydrolysis is typical of HDL cholesteryl ester hydrolysis (63) . Another possible explanation behind the higher Dil accumulation may be due to greater free cholesterol efflux induced by TNFɑ. Thus, it has been reported that TNFɑ enhances cholesterol efflux (78) and ABCA1 mRNA and protein through NF-kB signaling (93) .

It has been reported that TNFɑ enhances ACAT1 activity in leukocytic cells and promotes cholesteryl ester accumulation in the presence of oxLDL (70). This was not observed in the non-leukocytic cells tested (70). Enhanced cholesterol esterification as the primary mechanism underlying TNFɑ-induced cholesterol accumulation in pHAECs was not observed in this study. Of note, TNFɑ and oxidative stress are known to upregulate the oxLDL receptor, lectin-like oxLDL receptor (LOX-1) in arterial endothelial cells (94, 95) . Elevated cholesterol loading may secondarily elevate ACAT activity (96) . The extent to which the mechanism contributed to the findings is unclear. Cell culture and incubations. pHAECs (passages 3-7) were maintained in VBM with growth factor kit (VEGF), ATCC, in the presence of 15% FBS, and antibiotic, antimycotic (100 units/mL of penicillin, 100 µg/mL of streptomycin, and 0.25 µg/mL of amphotericin B, from Thermofisher). Under serum-free conditions, the cells were cultured in VBM, VEGF, with the latter antimicrobials and 0.1% FAF-BSA. Incubations were at 37 °C, unless indicated otherwise. Experiments were best started with pHAECs confluent for 5 days or longer. Separate cells from individuals (2-36 years old) were used during the course of the experiments, with similar results. Overnight incubations in serum medium were 24 ± 5 hours. For cell-associated studies at 37 ºC, cells were washed 3X with mHBSS at 0 ºC. Imaging studies demonstrated that the vast majority of dil-lipoproteins were within the cell under these conditions. For intracellular LDL levels, pHAECs were incubated at 0 °C for 5 minutes with ice cold 400 units/ml sodium heparin in mHBSS, washed twice with the same buffer, then two more times with ice cold mHBSS, to remove surface LDL. Lipids were extracted as described below or the cells were fixed with 4% paraformaldehyde in PBS prior to microscopy.

Lipoprotein purification. All procedures were performed between 0 and 4 °C. Centrifugations and dialysis were performed at 4 °C. Lipoproteins were isolated from freshly drawn human blood anticoagulated with Na2EDTA (BioIVT). The blood was centrifuged at 4,000 g for 30 minutes to obtain the plasma. To the plasma, butylated hydroxytoluene (BHT) in DMSO was added to 45 µM (0.01%). Then, sequential density ultracentrifugations (97) were performed to obtain d<1.006 (VLDL), d=1.019-1.063 (LDL), or d=1.12-1.21 (HDL3) g/ml. Ultracentrifugations were done using type Ti70 rotor at 50,000 rpm for 20 (VLDL and LDL) or 48 hours (HDL3). The lipoproteins were dialyzed through ~4 kD molecular weight cutoff membrane in 3 successions against ~180 times dialysis buffer (DB): 10 mM Tris-HCl, 150 mM NaCl, 0.3 mM Na2EDTA, pH 7.5, with deionized water, in the dark, each lasting about 24 hours. After concentration using 3 kD MWCO centrifugal filters, the LDL was filtered through 0.2 µm membrane under sterile conditions. Lipoprotein contents were routinely verified by western blotting and coomassie staining. In addition, the cholesterol and cholesteryl ester contents were verified to be consistent with previous publications (98) (99) (100) . Lipoprotein concentrations represent the protein content throughout the manuscript.

Lipids were extracted with hexane: isopropanol (1:1) at room temperature for 3 hours, then the solvent was evaporated at room temperature using centrivap concentrator (Labconco). The extracted lipids were redissolved in isopropanol.

To determine the unesterified cholesterol content, the lipids in isopropanol were mixed with 10 times volumes of cholesterol assay buffer (CAB): 0.1% fatty acid free BSA (Sigma), 2 mM sodium taurocholate (Beantown Chemical), 50 mM Tris-HCl, pH 7.5, 0.3 mM Na2EDTA, 5% isopropanol, and 250 mM sucrose, with freshly added 0.5 U/ml horseradish peroxidase (Thermofisher) and 0.02 U/ml cholesterol oxidase (Sigma) in the presence of 30-50 µM scopoletin (101) (excitation 360, emission 460). The CAB was kept at room temperature to ensure full solubilization of the lipids. (Due to the presence of organic solvents, it is recommended that N95 mask be worn). This enzymatic approach is a modification of a previously published procedure (102) . Total cholesterol was determined as above, with the addition of 0.1 U/ml cholesteryl esterase (MP Biologicals). Readings were obtained after incubation at 37 °C for 20 minutes. Cholesteryl esters were determined by subtracting unesterified cholesterol from the total cholesterol. The residual cell matter after lipid extraction was lysed with 0.1 M NaOH, 0.1% SDS, for protein reading using BCA assay kit (Thermofisher).

was added in 10 µl aliquots to 40 ml of 0.2 µm filtered human serum under sterile conditions. The mixture was incubated at 37 °C for 48 hours in the dark. 3 H-cholesteryl esters and other lipids were extracted with chloroform: methanol (103) . After evaporation of the solvent, the residue was dissolved in a minimal volume of chloroform. Subsequently, 3 H-cholesteryl esters were purified using serial bond elut columns (Agilent Technologies) with several hexane passages, as previously described (104) .

Western blotting. pHAECs were lysed with lysis buffer (0.2 % SDS, 2% Triton X-100, PBS, pH 7.5, 2% protease inhibitor and 2% phosphatase inhibitor, Sigma) by sonication at 2 setting (Fisher sonic dismembrator model 100) on ice for 10 seconds. After centrifugation at 16,000 g x 10 minutes at 4 °C, equal volume of loading buffer (8 M urea, 2% SDS, 125 mM Tris-HCl, pH 7.0, 5% glycerol, 10% betamercaptoethanol, 0.06% bromphenol blue) was mixed with the supernatant at room temperature. This was followed by electrophoresis, electrical transfer to PVDF membrane, and immunoblotting.

Generation of Dil-labeled lipoproteins was obtained essentially as previously described (105), with minor modifications. In brief, a mixture of about 2 mg HDL3, LDL, or VLDL protein and 7 ml of human lipoprotein deficient serum was mixed with ~1 mg [ 3 H]CE and/or 0.5 mg Dil in 10 µl DMSO aliquots under sterile conditions. In the case of VLDL, 100 µg apoE3 was included to obtain Dil-apoE3-VLDL. After covering with foil, the mixture was incubated at 37 °C for 21 hours. The lipoproteins were repurified as described above, after adjusting to their respective densities with solid KBr. Combined Dil, [ 3 H]CE-LDL radioactivity was 8.1 dpm/µg protein.

LDL iodination with Na 125 I. About 2 mg LDL protein in PBS and 10 iodination beads (Thermofisher) were incubated with Na 125 I for 10 minutes at room temperature in glass vials. The transformation was stopped with 50 mM each of unlabeled sodium iodide and sulfite, and 100 µM BHT in DMSO (0.01%). The labeled LDL was washed with desalting columns, then passed through centrifugal filters, 3 kD MWCO, against dialysis buffer. 125 I-LDL cell surface binding. Confluent pHAECs on plastic dishes were cultured with 0 or 5 ng/ml TNFɑ in 15% serum for 48 hours. Treatment continued with serum-free medium in the continued presence of TNFɑ for 3 hours to deplete surface-bound LDL. Subsequently, 125 I-LDL was added to 15 µg/ml for 1 hour at 37 °C. The cells were then washed two times with PBS at room temperature, then chilled on ice. Afterwards, serum-free medium at 4 °C with 0 (buffer) or 300 µg/ml LDL was added. Following additional incubation at 4 °C for 1 hour, the radioactivity released to the medium was taken as surface-releasable 125 I-LDL. LDL oxidation. LDL was dialysed against PBS at 4 °C, passed through 0.2 µm filter, and incubated at 37 °C for 22 hours with 5 µM CuSO4 in PBS under sterile conditions. After adding BHT in DMSO (0.005%) to 1 µM and Na2EDTA to 10 mM, the mixture was dialysed against dialysis buffer, and finally filtered through 0.2 µm membrane under sterile conditions.

Intact 125 I-LDL was separated from non-intact LDL using dextran sulfate, Mn 2+ procedure essentially as previously described (106) . To the BL medium, d<1.21 g/ml FBS was added to 15% to produce a visible precipitate, mixed, then dextran sulfate and MnCl were added to 65 mg/ml and 0.2 M, respectively. After incubation for 20 minutes at room temperature, the mixtures were centrifuged at 5000 g x 5 minutes at 4 °C. The pellet was redissolved with 20 mg/ml dextran sulfate before scintillation counting.

Surface LDLR Detection. Confluent pHAECs in serum medium were incubated with 0 or 100 ng/ml TNFɑ for 20-24 hours. Subsequently, the media were replaced with serum-free medium containing 10 µg/ml normal goat IgG or LDLR Ab (R&D Systems) in the continued presence of 0 or 100 ng/ml TNFɑ for 0, 5, 30, or 120 minutes at 37 ºC. Afterwards, the cells were chilled on ice and further incubated at 4 ºC for 1 hour. Then the cells were washed 2X with icecold mHBSS, fixed with ice-cold methanol at -20 ºC for 10 minutes, washed once with mHBSS at room temperature, then blocked with 50% human serum in mHBSS, 0.1% sodium azide (blocking buffer) for 1 hour at room temperature. Afterwards, it was replaced with 4 µg/ml red antigoat antibody (R&D Systems) in blocking buffer. Following 30 minute incubation at room temperature, the medium was replaced with mHBSS, washed 3X with blocking buffer (10 minutes each at room temperature), fixed with 4% paraformaldehyde in PBS, followed by fluorescence microscopy.

Fluorescence Microscopy. Fluorescence microscopy was performed using Keyence phase-contrast fluorescence microscope. Images were analyzed using CellProfiler (107) . Confocal microscopy was performed using glass bottom dishes (Cellvis).

Data are reported as averages ± standard deviation, where indicated. Analysis of variance, followed by Tukey post hoc testing was done by using statpages.info website.

DATA AVAILABILITY. All data are contained in the manuscript.

The author thanks the Meharry core facility staff for assistance in the using the equipment.

This work was supported through the following grants: Meharry Clinical and Translation Research Center (MeTRC) 5U54MD007593-09 (EUO, Samuel Adunyah), RCMI 5U54MD007586-33 (EUO, Samuel Adunyah), SC1HL101431(Hong Yang). Confocal microscopy core was supported through NIH grants MHD007586 and S10RR025497. The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.

The author declares that he has no conflicts of interest with the contents of this article esters were determined as described under Experimental Procedures. The data represent 5 independent experiments. C, Confluent pHAECs were pre-treated with 0 or 5 ng/ml TNFɑ in serum medium as described under Experimental Procedures. The amount of 125 I-LDL released to serum-free medium at 4 ºC without (0) or with 20 folds unlabeled LDL competitor (+) was determined as the surface 125 I-LDL. D, The experiment was performed as in E, and the amount of radioactivity associated with the cell was determined. C-D are representative of 3 experiments. Error bars represent standard deviations. *,**,***, p< 0.05, 0.01, 0.001, respectively, relative to the corresponding Ctrl.

Cells were treated with 0 (Ctrl) or 100 ng/ml TNFɑ (TNFɑ) for 24 hrs in serum medium. The media were replaced with serum-free media in the continued presence of TNFɑ for 2 hrs to remove surface lipoproteins. Finally, 2 µg/ml dil-LDL in serum-free medium (Dil-LDL) containing 40 times LDL (+40X LDL) or oxLDL (+40X oxLDL) was added. Following 2 hr incubation, the cells were washed 3X with mHBSS, then fixed with paraformaldehyde. Images in A are typical of 3 independent experiments, B. Error bars represent standard deviations. C, Coomassie stain of two batches of electrophoresed LDL and oxLDL proteins isolated during the course of the experiments. Positions of apoB and apoE are indicated. Afterwards, the cells were cultured in the presence of 0.05% DMSO vehicle, or the vehicle plus 50 µM BLT-1 (SR-B1 inhibitor), 12.5 µg/ml human PCSK9 (ApoER, LDLR, LRP, and VLDLR inhibitor), or 21 µg/ml human RAP (ApoER2, LRP, and VLDLR inhibitor) in serum-free medium for 1 hr. Lastly, 8 µg/ml dil-LDL was added, followed by 4 hr incubation. The data are representative of 3 independent experiments. C, Mouse immorto hepatocytes were incubated in serum-free RPMI 1640 medium containing the indicated inhibitors as above for 1 hr. Lastly, the hepatocytes were incubated with 10 µg/ml dil-HDL3, -LDL, or apoE-VLDL, as indicated, for 2 hrs. Error bars represent standard deviations.**,***, p< 0.01, 0.001, respectively. NS = not significant.

Confluent pHAECs were pre-treated with 0 or 100 ng/ml TNFa (+) in serum medium for 24 hrs. The cells were then cultured in serum-free medium in the continued presence of TNFɑ without any antibody (None), 18 µg/ml normal goat IgG control (Ctrl) or goat LDLR antibody (LDLR) for 3 hrs. Cellular LDLR and GAPDH were detected by immunoblottig. It can be seen in A that the LDLR Ab is selective for the LDLR. The data are representative of 3 independent experiments. Error bars represent standard deviations. NS = not significant. which pHAECs were grown to confluence on 3 µm polycarbonate filters, with 125 I-LDL in the AP medium. B, pHAECs in serum medium were pre-treated with 0 (Ctrl) or 5 ng/ml TNFɑ on the BL side for 48 hrs. Then 10 µg/ml 125 I-LDL without serum was added to the AP side (No Competitor) or with 30 folds unlabeled LDL (Unlabeled Competitor), in the continued presence of TNFɑ. After 3 hours, the BL media were collected, and non-intact 125 I-LDL was measured as described under Experimental Procedures. C, The experiment was performed as in B, followed by detection of intact BL 125 I-LDL. The data are representative of 3 independent experiments. Error bars represent standard deviations.*,**, p< 0.05, 0.01, respectively, Figure 11 . TNFɑ does not affect AP to BL LDL lipid release. A-D, pHAECs were pre-treated as in Figure 10 with 0, 10, or 100 ng/ml TNFɑ for 24 hrs in serum. Subsequently, 20 µg/ml control normal goat IgG (Goat IgG) or LDLR antibody (LDLR Ab) was added to the AP medium without serum for 2 hrs. Finally, 1.6 mg/ml double labeled Dil,[ 3 H]CE-LDL was added to the AP medium for 3 hrs. After heparin wash, the intracellular fluorescence (A-B), 3 H radioactivity (C), or medium BL 3 H (D) was determined. E, The cells were treated for 3 or 24 hrs with 0 (Ctrl) or 100 ng/ml TNFɑ without serum in the presence of apical Dil-LDL, and the BL fluorescence was determined. The images in A are from a single experiment. The data are representative of 3 independent experiments. Error bars represent standard deviations. NS = not significant. 

An endotoxin-induced serum factor that causes necrosis of tumors

Tumour necrosis factor and cancer

Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey

Tumour necrosis factor signalling in health and disease

A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF

Processing of newly synthesized cachectin/tumor necrosis factor in endotoxin-stimulated macrophages

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants -past, present and future

Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop

Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT

Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro

Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo

Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis

Signal transduction by tumor necrosis factor mediated by JNK protein kinases

Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes

Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses

Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors

TNFR2 interposes the proliferative and NF-kappaB-mediated inflammatory response by podocytes to TNF-alpha

Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1

Macrophage-derived tumor necrosis factor-alpha is an early component of the molecular cascade leading to angiogenesis in response to aortic injury

Induction of vascular endothelial growth factor gene expression by proinflammatory cytokines in human pulp and gingival fibroblasts

Proinflammatory Cytokines Increase Vascular Endothelial Growth Factor Expression in Alveolar Epithelial Cells

Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice

Exclusive expression of transmembrane TNF-alpha in mice reduces the inflammatory response in early lipid lesions of aortic sinus

Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice

Detection and localization of tumor necrosis factor in human atheroma

Tumor necrosis factor gene expression in human vascular intimal smooth muscle cells detected by in situ hybridization

Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells

High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL

Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells

Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant

Monocyte chemoattractant protein-1 (MCP-1): an overview

Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice

Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice

Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55

Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis

Absence of p55 TNF receptor reduces atherosclerosis, but has no major effect on angiotensin II induced aneurysms in LDL receptor deficient mice

Lesion progression and plaque composition are not altered in older apoE-/-mice lacking tumor necrosis factor-alpha receptor p55

Decreased atherosclerosis in mice deficient in tumor necrosis factor-alpha receptor-II (p75)

High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study

Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

Advancing age and insulin resistance: role of plasma tumor necrosis factor-alpha

Tumor necrosis factor-alpha in human arterial wall with atherosclerosis

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

Associations of Blood Pressure and Cholesterol Levels During Young Adulthood With Later Cardiovascular Events

Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-alpha expression

Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients

Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis

Human atherosclerosis. I. Cell constitution and characteristics of advanced lesions of the superficial femoral artery

Lipoproteins containing apo B extracted from human aortas. Structure and function

Canine hyperlipoproteinemia and atherosclerosis. Accumulation of lipid by aortic medial cells in vivo and in vitro

Role of contact inhibition in the regulation of receptor-mediated uptake of low density lipoprotein in cultured vascular endothelial cells

Changes in the endothelium of the aorta and the behaviour of macrophages in experimental atheroma of rabbits

Implications of early structural-functional changes in the endothelium for vascular disease

Studies on the pathogenesis of atherosclerosis. I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats

Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein, JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immunoglobulin G. Evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase

Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production

Last step in the path of LDL cholesterol from lysosome to plasma membrane to ER is governed by phosphatidylserine

Expression cloning of SR-BI, a CD36-related class B scavenger receptor

Scavenger receptor class B type I mediates the selective uptake of highdensity lipoprotein-associated cholesteryl ester by the liver in mice

SR-BI-directed HDL-cholesteryl ester hydrolysis

binds to multiple receptors and can be functionally inhibited by an EGF-A peptide

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)

The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor

39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor

Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb

TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation

Inhibition of acylcoenzyme A:cholesterol acyltransferase stimulates cholesterol efflux from macrophages and stimulates farnesoid X receptor in hepatocytes

Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins

Stimulation of cholesteryl ester synthesis in macrophages by extracts of atherosclerotic human aortas and complexes of albumin/cholesteryl esters

Enhanced macrophage uptake of low density lipoprotein after self-aggregation

Effect of arterial proteoglycans on the interaction of LDL with human monocyte-derived macrophages

Insoluble low-density lipoproteinproteoglycan complexes enhance cholesteryl ester accumulation in macrophages

Interaction of LDL with human arterial proteoglycans stimulates its uptake by human monocyte-derived macrophages

Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis

A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier

Visualization of the binding, endocytosis, and transcytosis of low-density lipoprotein in the arterial endothelium in situ

Identification of scavenger receptor SR-BI as a high density lipoprotein receptor

Scavenger receptor class B, type I, mediates selective uptake of low density lipoprotein cholesteryl ester

High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1

Structure of an LDLR-RAP complex reveals a general mode for ligand recognition by lipoprotein receptors

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

Unleashing endogenous TNF-alpha as a cancer immunotherapeutic

Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells

Tumor Necrosis Factor Inhibitors

Canine lipoproteins and atherosclerosis. I. Isolation and characterization of plasma lipoproteins from control dogs

Saturation and suppression of hepatic lipoprotein receptors: a mechanism for the hypercholesterolemia of cholesterol-fed rabbits

Cholesterol esters selectively taken up from highdensity lipoproteins are hydrolyzed extralysosomally

TNFalpha induces ABCA1 through NF-kappaB in macrophages and in phagocytes ingesting apoptotic cells

Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells

Redox-sensitive regulation of lox-1 gene expression in vascular endothelium

Cholesterol loading in macrophages stimulates formation of ER-derived vesicles with elevated ACAT1 activity

The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum

Lipid composition of human serum lipoproteins

Composition, concentration, and size of low density lipoproteins and of subfractions of very low density lipoproteins from serum of normal men and women

Plasma lipoproteins: apolipoprotein structure and function

A sensitive method for the estimation of hydrogen peroxide in biological materials

Enzymatic determination of total serum cholesterol

A rapid method of total lipid extraction and purification

Rapid separation of lipid classes in high yield and purity using bonded phase columns

Acetoacetylated lipoproteins used to distinguish fibroblasts from macrophages in vitro by fluorescence microscopy

Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions

CellProfiler 3.0: Next-generation image processing for biology

Abbreviations: ACAT, acyl-CoA cholesterol acyltransferase; AP, apical; apoE , apolipoprotein E; BHT, butylated hydroxytoluene; BL, basolateral; CAB, cholesterol assay buffer, DB, dialysis buffer; DiL, 1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate; DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; FAF-BSA, fatty acid-free bovine serum albumin; FBS, fetal bovine serum; LDLR, low density lipoprotein receptor; LRP, ldlr-related protein; mHBSS, modified Hanks' balanced salt solution; PBS, phosphate buffered saline; PCSK9, proprotein convertase subtilisin/kexin type 9; PhenA, 1,10-phenanthroline; pHAECs, primary human aortic endothelial cells; RAP, receptor associated protein; SDS, sodium dodecyl sulfate; TMTU, tetramethylthiourea; TNFɑ, tumor necrosis factor alpha; VBM, vascular basal medium; VEGF, vascular endothelial growth factor kit;